TherapeuticsMD (TXMD) Short term Debt (2011 - 2022)
TherapeuticsMD's (TXMD) quarterly Short term Debt came in at $93.6 million in Q3 2022, up 524.01% YoY from $15.0 million in Q3 2021, and up 3.11% on a QoQ basis from $90.8 million in Q2 2022.
TherapeuticsMD (TXMD) Short term Debt (2011 - 2022) Analysis & Trends
TherapeuticsMD (TXMD) has 4 years of Short term Debt data on file, last reported at $93.6 million in Q3 2022.
- Quarterly Short term Debt rose 524.01% year-over-year to $93.6 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $93.6 million (up 524.01% YoY) and the FY2021 annual result came in at $188.3 million, changed N/A from the prior year.
- Short term Debt improved to $93.6 million in Q3 2022, from $90.8 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $202.9 million in Q1 2022 to a low of $5.0 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | TherapeuticsMD | 23.78 Mn | 14.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 93.60 Mn |
| Jun 30, 2022 | 90.78 Mn |
| Mar 31, 2022 | 202.86 Mn |
| Dec 31, 2021 | 188.27 Mn |
| Sep 30, 2021 | 15.00 Mn |
| Jun 30, 2021 | 10.00 Mn |
| Mar 31, 2021 | 5.00 Mn |
| Mar 31, 2013 | 100,000.00 |
| Dec 31, 2011 | 2.15 Mn |